The oncogenic role of HBXIP - 19/12/20
pages | 9 |
Iconographies | 5 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Hepatitis B X-interacting protein (HBXIP) is a conserved protein of 19 kDa that was originally identified as a binding partner of hepatitis B virus X protein. Emerging evidence indicates that HBXIP is highly expressed in a variety of cancers and is correlated with poor clinical outcomes in cancer patients. HBXIP plays a critical role in cancer progression, but the underlying mechanisms are still unclear. In this review, we primarily focus on publications investigating HBXIP in cancer research, including its expression and clinical significance in cancer patients, its role as a coactivator of transcription factors in cancer cells, its inhibitory effects on the mitochondrial cytochrome c-caspase apoptotic pathway, as well as its roles in promoting mitosis and drug resistance in cancer cells, its regulatory effects on cancer metabolism, and its relationships with other signaling pathways or microRNAs in cancer. This review aims to compile and summarize existing knowledge of the functions of HBXIP in cancer, which provides a comprehensive reference for future studies on the oncogenic mechanisms of HBXIP.
Le texte complet de cet article est disponible en PDF.Abbreviations : Cdc42, Apaf1, PIN1, ERK, KEAP1, ATM, ATR, HOXB13, STAT4, NF-κB, HIF1α, ROS, PI3K, Akt, PDGFB, IL-8, MST1, STAT3, PTEN, S100A4, VEGF, Capn4
Keywords : HBXIP, Oncogenic, Cancer
Plan
Vol 133
Article 111045- janvier 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?